nach oben

Tumor Biology

Erschienen in:

01.04.2015 | Research Article

Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes

verfasst von: Rouhallah Najjar Sadeghi, Fatemeh Karami-Tehrani, Siamak Salami

Erschienen in: Tumor Biology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Glycolysis has been shown to be required for the cell growth and proliferation in several cancer cells. However, prostate cancer cells were accused of using more fatty acid than glucose to meet their bioenergetic demands. The present study was designed to evaluate the involvement of hexokinase and CPT-1 in the cell growth and proliferation of human prostate cancer cell lines, PC3, and LNCaP-FGC-10. Hexokinase and CPT-1 activities were examined in the presence of different concentrations of their inhibitors, lonidamine and etomoxir, to find the concentration of maximum inhibition ([I _max]). To assess cell viability and proliferation, dimethylthiazol (MTT) assay was carried out using [I _max] for 24, 48, and 72 h on PC3 and LNCaP cells. Apoptosis was determined using annexin-V, caspase-3 activity assay, Hoechst 33258 staining, and evaluation of mitochondrial membrane potential (MMP). Moreover, ATP levels were measured following lonidamine and etomoxir exposure. In addition, to define the impact of exogenous fatty acid on the cell growth and proliferation, CPT-1 activity was evaluated in the presence of palmitate (50 μM). Hexokinase and CPT-1 activities were significantly inhibited by lonidamine [600 μM] and etomoxir [100 μM] in both cell lines. Treatment of the cells with lonidamine [600 μM] resulted in a significant ATP reduction, cell viability and apoptosis, caspase-3 activity elevation, MMP reduction, and appearance of apoptosis-related morphological changes in the cells. In contrast, etomoxir [100 μM] just decreased ATP levels in both cell lines without significant cell death and apoptosis. Compared with glucose (2 g/L), palmitate intensified CPT-1 activity in both cell lines, especially in LNCaP cells. In addition, activity of CPT-1 was higher in LNCaP than PC3 cells. Our results suggest that prostate cancer cells may metabolize glucose as a source of bioenergetic pathways. ATP could also be produced by long-chain fatty acid oxidation. In addition, these data might suggest that LNCaP is more compatible with palmitate.

Warburg O. Über den stoffwechsel menschlicher tumorzellen. J Mol Med. 1925;4:2396–7.

Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–43.CrossRefPubMed

Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006;66:632–7.CrossRefPubMed

Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007;26:299–310.CrossRefPubMed

Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.CrossRefPubMed

Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70:2465–75.CrossRefPubMed

Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, et al. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther. 2008;7:3546–55.CrossRefPubMed

Singh G, Lakkis CL, Laucirica R, Epner DE. Regulation of prostate cancer cell division by glucose. J Cell Physiol. 1999;180:431–8.CrossRefPubMed

Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230–4.CrossRefPubMed

10.

Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res. 2010;30:369–74.PubMed

11.

Sinha K. Elevated α-methylacyl-CoA racemase enzymatic activity. Am J Pathol2004;164:787-793

12.

Rubin M, Zhou M, Dhanasekaran SM. α-Methylacyl-CoA racemase as tissue biomarker of PC. JAMA 2002;287:1662-1670

13.

Luo J, Zha S, Gage WR, Dunn TA, et al. α-Methylacyl-CoA racemase; a new molecular marker for prostate cancer. Cancer Res 2002; 62:2220–2226.

14.

Jiang Z, W.B.A., Rock K L, Xu Y, Savas L, Khan A, et al., P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001; 25:13971404.

15.

Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002; 26:926-931.

16.

Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, et al. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate. 2005;63:316–23.CrossRefPubMed

17.

Brawer MK. Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol. 2005;7(7):S21–6.PubMedPubMedCentral

18.

Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, de Martino C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst. 1981;66:497–9.PubMed

19.

Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, et al. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res. 1981;41:4661–6.PubMed

20.

Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci. 1977;74:3735–9.CrossRefPubMedPubMedCentral

21.

Xu FY, Taylor WA, Hurd JA, Hatch GM. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J Lipid Res. 2003;44:415–23.CrossRefPubMed

22.

Morillas M, Clotet J, Rubí B, Serra D, Arino J, Hegardt F, et al. Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced through the co-ordinate interaction with two histidine residues. Biochem J. 2000;351:495–502.CrossRefPubMedPubMedCentral

23.

Gerondaes P, Alberti K, Agius L. Interactions of inhibitors of carnitine palmitoyltransferase I and fibrates in cultured hepatocytes. Biochem J. 1988;253:169–73.CrossRefPubMedPubMedCentral

24.

Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem. 2001;276:14890–5.CrossRefPubMed

25.

Robey RB, Raval BJ, Ma J, Santos AV. Thrombin is a novel regulator of hexokinase activity in mesangial cells. Kidney Int. 2000;57:2308–18.CrossRefPubMed

26.

Karlic H, Lohninger S, Koeck T, Lohninger A. Dietary l-carnitine stimulates carnitine acyltransferases in the liver of aged rats. J Histochem Cytochem. 2002;50:205–12.CrossRefPubMed

27.

Salami S, Karami-Tehrani F. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem. 2003;36:247–53.CrossRefPubMed

28.

Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA. Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques. 2011;50:98.CrossRefPubMedPubMedCentral

29.

Srinivasan S, Stevens M, Wiley JW. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes. 2000;49:1932–8.CrossRefPubMed

30.

Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 1995;45:81–6.CrossRefPubMed

31.

Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1:707–15.PubMed

32.

Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, et al. Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer. 1995;62:216–22.CrossRefPubMed

33.

Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049–57.CrossRefPubMed

34.

Kumaravel G, Gandour R, Krueger M, Ramsay R. Comparison of the active sites of the purified carnitine acyltransferases from peroxisomes and mitochondria by using a reaction-intermediate analogue. Biochem J. 1993;294:645–51.CrossRefPubMedPubMedCentral

35.

Murthy M, Pande SV. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci. 1987;84:378–82.CrossRefPubMedPubMedCentral

36.

Pimenta AS, Gaidhu MP, Habib S, So M, Fediuc S, Mirpourian M, et al. Prolonged exposure to palmitate impairs fatty acid oxidation despite activation of AMP-activated protein kinase in skeletal muscle cells. J Cell Physiol. 2008;217:478–85.CrossRefPubMed

37.

Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol. 2011;18:846–56.CrossRefPubMedPubMedCentral

38.

Higgins L, Withers H, Garbens A, Love H, Magnoni L, Hayward S, et al. Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim Biophys Acta (BBA)-Bioenerg. 2009;1787:1433–43.CrossRef

39.

Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011;25:1041–51.CrossRefPubMedPubMedCentral

40.

Ruderman NB, Dean D. Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle. J Basic Clin Physiol Pharmacol. 1998;9:295–308.CrossRefPubMed

41.

Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta (BBA)-Bioenerg. 2011;1807:726–34.CrossRef

42.

Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013;105–10.

43.

Lu W, Pelicano H, Huang P. Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell. 2010;18:199–200.CrossRefPubMedPubMedCentral

44.

Pouyssegur J, Franchi A, Silvestre P. Relationship between increased aerobic glycolysis and DNA synthesis initiation studied using glycolytic mutant fibroblasts. Nature. 1980;287:445–7.CrossRefPubMed

45.

Jannière L, Canceill D, Suski C, Kanga S, Dalmais B, Lestini R, et al. Genetic evidence for a link between glycolysis and DNA replication. PLoS One. 2007;2:e447.CrossRefPubMedPubMedCentral

46.

Farese RV, Standaert ML, Arnold TP, Yamada K, Musunuru K, Hernandez H, et al. Preferential activation of microsomal diacylglycerol/protein kinase C signaling during glucose treatment (de novo phospholipid synthesis) of rat adipocytes. J Clin Investig. 1994;93:1894–9.CrossRefPubMedPubMedCentral

47.

Miele C, Paturzo F, Teperino R, Sakane F, Fiory F, Oriente F, et al. Glucose regulates diacylglycerol intracellular levels and protein kinase C activity by modulating diacylglycerol kinase subcellular localization. J Biol Chem. 2007;282:31835–43.CrossRefPubMed

48.

Burg JS, Espenshade PJ. Glucose controls phosphoregulation of HMG-CoA reductase through the PP2A-related phosphatase Ppe1 and Insig in fission yeast. J Biol Chem. 2011;111:233452.

49.

Mathews EH, Liebenberg L, Pelzer R. High-glycolytic cancers and their interplay with the body’s glucose demand and supply cycle. Med Hypotheses. 2011;76:157–65.CrossRefPubMed

50.

Zhang A, Wu Y, Lai H, Yew D. Apoptosis—a brief review. Neuroembryol Aging. 2005;3:47–59.CrossRef

Titel: Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes
verfasst von: Rouhallah Najjar Sadeghi
Fatemeh Karami-Tehrani
Siamak Salami
Publikationsdatum: 01.04.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2919-4

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1

The methylenetetrahydrofolate reductase (MTHFR) 677 C>T polymorphism increases the risk of developing chronic myeloid leukemia—a case-control study

Genome-wide haplotype association study identifies BLM as a risk gene for prostate cancer in Chinese population

Association of IL-10 GTC haplotype with serum level and HPV infection in the development of cervical carcinoma

p53 suppresses CCL2-induced subcutaneous tumor xenograft

Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie